Drugs With Better Sales Have Better Development Times, Study Finds
Executive Summary
Drugs with strong sales were developed more quickly than drugs with weaker sales, according to an analysis published in the March/April issue of Health Affairs
You may also be interested in...
Lilly Aims To Lower NME Cost To $800 Mil. Via Incremental Improvements
Lilly is aiming for a 33% reduction in the cost of launching a new molecular entity by 2010 through incremental improvements in several stages of the drug developmental process
Lilly Aims To Lower NME Cost To $800 Mil. Via Incremental Improvements
Lilly is aiming for a 33% reduction in the cost of launching a new molecular entity by 2010 through incremental improvements in several stages of the drug developmental process
Key To First-Cycle Approval Is To Meet Early And Often, Consultants Tell FDA
An independent analysis of FDA's first-cycle review performance provides support for the agency's request for additional funding for pre-submission meetings